All In Biotech

Drug Trial Radar · NCT07422480

A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Transfusions

A Phase 3, Multicenter, Open-Label, Randomized Trial to Compare the Efficacy and Safety of Elritercept Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in ESA-naïve Adult Participants Who Require Red Blood Cell Transfusions

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 300 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

300

Planned (sponsor's estimate)

Start

May 21, 2026

Primary completion

Apr 30, 2029

Study completion Oct 1, 2033

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Feb 20, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main aim of this study is to assess how much elritercept reduces the need for RBC (red blood cell) transfusions and improves hemoglobin blood values in addition to how safe elritercept is when compared with epoetin alfa. Other key aims are to learn how much elritercept improves tiredness and quality of life as reported by participants compared with epoetin alfa; to assess what risks (side effects) and how often they occur with elritercept compared with epoetin alfa. The study will also collect information for researchers to see how the disease in the bone marrow or other body areas may be affected by elritercept compared with epoetin alfa to try to learn how to better treat this disease.

Conditions

  • Myelodysplastic Syndrome
  • Anemia

Interventions

  • ElriterceptDrug

    Elritercept, SC injection.

  • Epoetin AlfaDrug

    Epoetin Alfa, SC injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Participants who are RBC Transfusion Independent (RBC-TI) for any Consecutive Greater Than Equal to (≥) 12-Week Period From Day 1 Through 24 Weeks With Concurrent Mean Hemoglobin (Hgb) Increase ≥ 1.5 Grams per Deciliter (g/dL) From BaselineTime frame: From Cycle 1 Day 1 through Week 24 (each cycle is 28 days)

Locations

166 sites in 28 countries. Site status is shown where the registry gives one.

  • Banner MD Anderson Cancer Center

    Gilbert, Arizona · Not yet recruiting

  • City of Hope - Comprehensive Cancer Center (CCC)

    Duarte, California · Not yet recruiting

  • Providence Medical Group

    Santa Rosa, California · Not yet recruiting

  • Cancer & Blood Research Center

    Whittier, California · Not yet recruiting

  • Yale

    New Haven, Connecticut · Not yet recruiting

  • Florida Oncology & Hematology

    Fort Myers, Florida · Not yet recruiting

  • University of Miami

    Miami, Florida · Not yet recruiting

  • BRCR Medical Center Inc

    Tamarac, Florida · Recruiting

  • Moffitt Cancer Center

    Tampa, Florida · Not yet recruiting

  • Emory University

    Atlanta, Georgia · Recruiting

  • Saint Luke's Cancer Institute

    Boise, Idaho · Not yet recruiting

  • Orchard Healthcare Research Inc. (OHR) - Skokie

    Skokie, Illinois · Recruiting

  • Norton Cancer Institute

    Louisville, Kentucky · Recruiting

  • Epic Medical Research

    Monroe, Louisiana · Not yet recruiting

  • Epic Medical Research - Shreveport

    Shreveport, Louisiana · Not yet recruiting

  • The Cancer and Hematology Centers

    Grand Rapids, Michigan · Not yet recruiting

  • American Oncology Partners P.A. MidAmerica Cancer Care

    Kansas City, Missouri · Recruiting

  • Icahn School of Medicine at Mount Sinai

    New York, New York · Not yet recruiting

  • Hematology Oncology Associates of Rockland

    Nyack, New York · Not yet recruiting

  • UR Medicine (University of Rochester Medical Center)

    Rochester, New York · Not yet recruiting

  • Albert Einstein College - Montefiore

    The Bronx, New York · Recruiting

  • Novant Health Care Institute

    Winston-Salem, North Carolina · Not yet recruiting

  • Cleveland clinic OH

    Cleveland, Ohio · Not yet recruiting

  • Thomas Jefferson University

    Philadelphia, Pennsylvania · Not yet recruiting

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania · Recruiting

  • Tennessee Oncology, PLLC

    Nashville, Tennessee · Recruiting

  • World Research Link

    Baytown, Texas · Recruiting

  • Texas Oncology - Denton

    Denton, Texas · Recruiting

  • The Center for Cancer and Blood Disorders

    Fort Worth, Texas · Recruiting

  • The University of Texas-MD Anderson Cancer Center - Leukemia Center

    Houston, Texas · Recruiting

  • LUMI Research

    Houston, Texas · Recruiting

  • Renovatio Clinical

    The Woodlands, Texas · Recruiting

  • Huntsman Cancer Institute

    Salt Lake City, Utah · Not yet recruiting

  • Virginia Commonwealth University (VCU)-Medical Center - North Hospital

    Richmond, Virginia · Not yet recruiting

  • West Virginia University Cancer Institute

    Wheeling, West Virginia · Recruiting

  • Swiss Medical Center - Barrio Parque

    Buenos Aires, Argentina · Recruiting

  • Sanatorio Allende S.A. - Nueva Cordoba

    Córdoba, Argentina · Not yet recruiting

  • Hospital Privado de Cordoba

    Córdoba, Argentina · Recruiting

  • Instituto Medico de la Fundacion Estudios Clinicos

    Rosario, Santa Fe Province, Argentina · Recruiting

  • Mid North Coast Local Health District - Mid North Coast Cancer Institute (MNCCI) - Coffs Harbour

    Coffs Harbour, New South Wales, Australia · Not yet recruiting

Showing 40 of 166 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.